CL2017001602A1 - Derivados de fumagilol. - Google Patents

Derivados de fumagilol.

Info

Publication number
CL2017001602A1
CL2017001602A1 CL2017001602A CL2017001602A CL2017001602A1 CL 2017001602 A1 CL2017001602 A1 CL 2017001602A1 CL 2017001602 A CL2017001602 A CL 2017001602A CL 2017001602 A CL2017001602 A CL 2017001602A CL 2017001602 A1 CL2017001602 A1 CL 2017001602A1
Authority
CL
Chile
Prior art keywords
compounds
fumagilol
derivatives
disorders
formula
Prior art date
Application number
CL2017001602A
Other languages
English (en)
Inventor
John David Lawson
Zacharia Cheruvallath
Christopher Mcbride
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of CL2017001602A1 publication Critical patent/CL2017001602A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

<p>SE DIVULGAN LOS COMPUESTOS DE FORMULA 1, ESTEREOISÓMEROS DE ESTOS Y SALES FARMACÉUTICAMENTE ACEPTABLES DE LOS COMPUESTOS Y ESTEREOLSÓMEROS, DONDE R 1Y R2 SE DEFINEN EN LA ESPECIFICACIÓN. ESTA DESCRIPCIÓN TAMBIÉN SE REFIERE A LOS MATERIALES Y MÉTODOS PARA PREPARAR LOS COMPUESTOS DE FORMULA 1, A LAS COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y A SU USO PARA TRATAR LA OBESIDAD Y ENFERMEDADES RELACIONADAS, TRASTORNOS Y DESORDENES RELACIONADOS CON METAP2.</p>
CL2017001602A 2014-12-19 2017-06-19 Derivados de fumagilol. CL2017001602A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462094823P 2014-12-19 2014-12-19

Publications (1)

Publication Number Publication Date
CL2017001602A1 true CL2017001602A1 (es) 2018-03-09

Family

ID=55071249

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017001602A CL2017001602A1 (es) 2014-12-19 2017-06-19 Derivados de fumagilol.

Country Status (25)

Country Link
US (2) US9827255B2 (es)
EP (1) EP3233870B1 (es)
JP (1) JP2018500329A (es)
KR (1) KR20170099973A (es)
CN (1) CN107207547A (es)
AR (1) AR103078A1 (es)
AU (1) AU2015364477A1 (es)
BR (1) BR112017012965A2 (es)
CA (1) CA2971282A1 (es)
CL (1) CL2017001602A1 (es)
CO (1) CO2017007189A2 (es)
CR (1) CR20170332A (es)
DO (1) DOP2017000138A (es)
EA (1) EA032431B1 (es)
EC (1) ECSP17045054A (es)
ES (1) ES2702026T3 (es)
IL (1) IL252908A0 (es)
MX (1) MX2017007926A (es)
PE (1) PE20171141A1 (es)
PH (1) PH12017501134A1 (es)
SG (1) SG11201704985VA (es)
TN (1) TN2017000254A1 (es)
TW (1) TW201636342A (es)
UY (1) UY36450A (es)
WO (1) WO2016100778A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201636342A (zh) 2014-12-19 2016-10-16 武田藥品工業有限公司 煙黴醇衍生物
US20210231682A1 (en) * 2018-04-20 2021-07-29 The University Of Vermont And State Agriculture College Compositions and methods for treating vascular disease in selected patients

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH26256A (en) 1988-08-12 1992-04-01 Fujisawa Pharmaceutical Co Oxaspiro [2,5] octane derivative
ATE150750T1 (de) 1988-09-01 1997-04-15 Takeda Chemical Industries Ltd Fumagillol-derivate
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
JPH1081631A (ja) * 1996-07-17 1998-03-31 Takeda Chem Ind Ltd 癌転移または再発抑制剤
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US6207704B1 (en) 1997-06-09 2001-03-27 Massachusetts Institute Of Technology Type 2 methionine aminopeptidase [MetAP2] inhibitors and uses thereof
US6306819B1 (en) 1997-10-31 2001-10-23 Massachusetts Institute Of Technology Method for regulating size of vascularized normal tissue
KR100357541B1 (ko) 1998-05-15 2002-10-18 주식회사종근당 5-데메톡시 푸마질롤 유도체 및 그 제조방법
KR100357542B1 (ko) * 1998-05-15 2002-10-18 주식회사종근당 푸마질롤 유도체 및 그 제조방법
EP1330447A2 (en) 2000-11-01 2003-07-30 Praecis Pharmaceuticals Incorporated Peptides as met-ap2 inhibitors
ATE440094T1 (de) 2001-09-27 2009-09-15 Equispharm Co Ltd Fumagillolderivate und verfahren zu deren herstellung
AU2003230852B2 (en) 2002-04-11 2008-07-10 Children's Medical Center Corporation TNP-470 polymer conjugates and use thereof
KR100552043B1 (ko) 2004-02-28 2006-02-20 주식회사종근당 푸마질롤 유도체를 포함하는 비만치료용 조성물
EP1841761A4 (en) * 2005-01-26 2008-10-29 Chong Kun Dang Pharm Corp Fumagillol derivatives or processes for the preparation of fumagillol derivatives, and pharmaceutical compositions containing them
FR2886855B1 (fr) 2005-06-08 2009-07-17 Agronomique Inst Nat Rech Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocyliques
US8399512B2 (en) 2007-11-28 2013-03-19 Mersana Therapeutics, Inc. Biocompatible biodegradable fumagillin analog conjugates
US8299067B2 (en) 2008-03-27 2012-10-30 Versitech Limited 5-demethoxyfumagillol and derivatives thereof
US20120004162A1 (en) 2008-12-04 2012-01-05 Vath James E Methods of Treating an Overweight or Obese Subject
US8642650B2 (en) 2008-12-04 2014-02-04 Zafgen, Inc. Methods of treating an overweight or obese subject
AU2011239414A1 (en) * 2010-04-15 2012-11-08 The Washington University Prodrug compositions, prodrug nanoparticles, and methods of use thereof
WO2011150338A1 (en) 2010-05-27 2011-12-01 Zafgen Corporation Methods of treating obesity
JP5876513B2 (ja) * 2011-03-08 2016-03-02 ザフゲン，インコーポレイテッド オキサスピロ［２．５］オクタン誘導体および類似体
FR2973376B1 (fr) 2011-03-28 2013-05-10 Atlanthera Derives utiles dans le traitement ou la prevention de tumeurs osseuses
TW201636342A (zh) 2014-12-19 2016-10-16 武田藥品工業有限公司 煙黴醇衍生物

Also Published As

Publication number Publication date
BR112017012965A2 (pt) 2018-01-09
MX2017007926A (es) 2017-09-27
US20160175332A1 (en) 2016-06-23
ES2702026T3 (es) 2019-02-27
CA2971282A1 (en) 2016-06-23
AR103078A1 (es) 2017-04-12
CR20170332A (es) 2017-10-05
EP3233870B1 (en) 2018-10-31
JP2018500329A (ja) 2018-01-11
US9827255B2 (en) 2017-11-28
PE20171141A1 (es) 2017-08-09
SG11201704985VA (en) 2017-07-28
AU2015364477A1 (en) 2017-07-13
EP3233870A1 (en) 2017-10-25
PH12017501134A1 (en) 2017-11-27
US10328089B2 (en) 2019-06-25
EA201791398A1 (ru) 2017-10-31
US20180050051A1 (en) 2018-02-22
ECSP17045054A (es) 2017-10-31
DOP2017000138A (es) 2017-07-31
EA032431B1 (ru) 2019-05-31
KR20170099973A (ko) 2017-09-01
UY36450A (es) 2016-07-29
TN2017000254A1 (en) 2018-10-19
CO2017007189A2 (es) 2017-10-20
IL252908A0 (en) 2017-08-31
CN107207547A (zh) 2017-09-26
WO2016100778A1 (en) 2016-06-23
TW201636342A (zh) 2016-10-16

Similar Documents

Publication Publication Date Title
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
ECSP22018571A (es) Degradadores bifuncionales de brd9 y sus métodos de uso
MX2021009673A (es) Moduladores de ror-gamma.
CL2018003135A1 (es) Derivados aromáticos de sulfonamida.
MX2018009257A (es) Derivados de benzimidazol como moduladores de ror-gamma.
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
PE20191474A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer
CL2018000542A1 (es) Nuevos derivados de fenoximetilo.
MX381707B (es) Nuevos derivados biciclicos, un proceso para su preparacion y composiciones farmaceuticas que los contienen.
CL2016002148A1 (es) Derivados de fenilen-1,5-diamina 2,4-disustituidos y aplicaciones de los mismos, y composiciones farmacéuticas y composiciones farmacéuticamente aceptables preparadas a partir de los mismos.
MX372716B (es) Nuevos derivados hidroxiéster, un proceso para su preparación y composiciones farmacéuticas que los contienen.
BR112016015838A8 (pt) compostos heterocíclicos aromáticos, composição farmacêutica compreendendo os referidos compostos e produto de combinação
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
CL2017001923A1 (es) Derivados de 9h-pirrolo-dipiridina
CL2017001073A1 (es) 2,4 diamino-quinolia sustituido como nuevos agentes anticancerigenos
CL2019001991A1 (es) Moduladores del receptor de estrógeno.
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
MX2018013519A (es) Inhibidores del potenciador del homologo zeste 2.
CO2019008110A2 (es) Activador de nrf2
CL2019002480A1 (es) Derivados de pirazol como inhibidores de bromodominio.
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
UY36732A (es) Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet
CL2017001602A1 (es) Derivados de fumagilol.
EA201790020A1 (ru) Соединения, фармацевтические композиции и их применение при лечении нейродегенеративных заболеваний
ECSP18056196A (es) Derivados de indano